Background People living with human immunodeficiency virus (PLHIV) have a similar
prevalence of psoriasis as the general population, though incidence and severity correlate …

Methods To investigate the efficacy and safety of systemic immunosuppressive therapies for
psoriatic disease in HIV-positive individuals, a PubMed search of articles indexed for …

Background Psoriasis is a chronic immune‐mediated inflammatory disorder that also occurs
in the setting of human immunodeficiency virus (HIV). Biological therapy has transformed the …

Background: The management of HIV-positive patients with psoriasis is controversial and
limited to individual cases or short series of patients. Objectives: To evaluate the safety and …

Background: The management of psoriatic disease in HIV-positive patients is challenging.
Psoriasis in HIV-positive patients is often severe, progressive, and resistant to first-and …

Background Patients with treated solid tumours (TSTs) are a highly heterogeneous
population at an increased risk for malignancy compared with the general population. When …

People living with HIV (PLWH) are affected by a higher incidence skin disorders, which are
often associated with high morbidity and mortality. In particular, psoriasis affects PLWH …

BACKGROUND: Patients with psoriasis and HIV infection often present with more severe
and treatment-refractory cutaneous disease. In addition, many of these patients have …

Human immunodeficiency virus (HIV) prevalence is increasing worldwide as people on
antiretroviral therapy are living longer. These patients are often susceptible to debilitating …

Psoriasis is a prevalent systemic immune-mediated disease with cutaneous manifestations.
In HIV-infected patients, psoriasis may have a higher incidence, present atypical and more …